Interacting Drugs |
Pioglitazone and metformin vs CYP2C8 Substrates (High risk) |
Security Level |
 |
Mechanism |
CYP2C8 Substrates (High risk): CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates (High risk). |
Management |
Monitor therapy |
Pioglitazone and metformin vs CYP2C8 Substrates (High risk)
Post Review about Pioglitazone and metformin vs CYP2C8 Substrates (High risk) Click here to cancel reply.
Other Interactions of Pioglitazone and metformin
Other Interactions of CYP2C8 Substrates (High risk)
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.